WO2010011119A1 - Solution ophtalmique pour épaissir les cornées - Google Patents
Solution ophtalmique pour épaissir les cornées Download PDFInfo
- Publication number
- WO2010011119A1 WO2010011119A1 PCT/MX2008/000095 MX2008000095W WO2010011119A1 WO 2010011119 A1 WO2010011119 A1 WO 2010011119A1 MX 2008000095 W MX2008000095 W MX 2008000095W WO 2010011119 A1 WO2010011119 A1 WO 2010011119A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ophthalmic solution
- corneas
- corneal
- riboflavin
- solution
- Prior art date
Links
- 229940054534 ophthalmic solution Drugs 0.000 title claims abstract description 31
- 239000002997 ophthalmic solution Substances 0.000 title claims abstract description 31
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 201000002287 Keratoconus Diseases 0.000 claims abstract description 16
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 12
- 239000001923 methylcellulose Substances 0.000 claims abstract description 12
- 235000010981 methylcellulose Nutrition 0.000 claims abstract description 12
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002477 riboflavin Drugs 0.000 claims abstract description 10
- 239000002151 riboflavin Substances 0.000 claims abstract description 9
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 9
- 208000031816 Pathologic Dilatation Diseases 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 8
- 206010054760 Corneal thinning Diseases 0.000 claims abstract description 4
- 201000007717 corneal ulcer Diseases 0.000 claims abstract description 4
- 239000012153 distilled water Substances 0.000 claims abstract description 3
- 239000003755 preservative agent Substances 0.000 claims abstract description 3
- 230000002335 preservative effect Effects 0.000 claims abstract description 3
- 210000004087 cornea Anatomy 0.000 claims description 47
- 230000008719 thickening Effects 0.000 claims description 11
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 229950001574 riboflavin phosphate Drugs 0.000 claims description 5
- 239000012154 double-distilled water Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 4
- 229960002900 methylcellulose Drugs 0.000 claims 4
- 239000003855 balanced salt solution Substances 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 238000012876 topography Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 5
- 201000009310 astigmatism Diseases 0.000 description 4
- 239000000835 fiber Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the present invention relates to the Science of Medicine, more specifically in Ophthalmology, since it provides an ophthalmological solution for thickening of the corneas, without the need to use ultraviolet light.
- keratoconus is formed by two other words of Greek origin: kerato, which means cornea and konos that means cone, is an uncommon condition where the cornea is affected by the thinning and protrusion of the same, this condition makes the Perception of images by the human eye is altered, causing poor vision progressively.
- keratoconus so far remains unknown;
- various surgical treatments mainly for the control of keratoconus, such as: corneal transplantation, the application of intrastromal rings, the application of radiofrequency pulses in certain places of the cornea to correct astigmatism generated by keratoconus, and application of riboflavin by ultraviolet light (corneal crosslinking) to favor the binding of the collagen fibers of the corneal stroma.
- a method for treating ophthalmic disorders of the cornea where there is lysis of the collagen by the action of collagenous enzymes; said method comprises Ia oral aministr ⁇ construación to a patient, once or four times a day, of a composition comprising: a compound selected from the group consisting of Cistine and Cysteine, from 200 to 1000 mg; and Pyridoxine (vitamin B ⁇ ) in the form of a base or salt, from 50 to 300 mg.
- ophthalmological disorders can be, keratoconus, corneal damage, corneal herpes, among others.
- the composition can be administered in tablets, so it is obvious the use of acceptable pharmaceutical excipients, such as sugars, carboxymethyl cellulose, talc, etc. In this case, the results are obtained in the long term, because the composition is administered orally.
- the "crosslinking" method consists in saturating Riboflavin eye tissue (vitamin B2) to sensitize the collagen and stimulate the creation of new bridges or junctions between the long collagen chains; and with the irradiation of a special wavelength of ultraviolet light, for 30 min and at a certain distance.
- Vitamin B2 Riboflavin eye tissue
- the disadvantages that this method presents, is that the epithelium of the cornea must be removed, exposing the patient's eye to ultra violet light; Because the patient is uncomfortable, it causes pain, vision is temporarily affected, it can cause photophobia and epiphora, and there is a risk of damage, when the amount of ultraviolet light to be applied is not well calibrated.
- intrastromal rings to stabilize the keratoconus
- it is also a method that requires corneal incisions, and then makes semi-moons in order to apply pmma rings and correct astigmatism caused by the keratoconus, the recovery being taken and may have complications ranging from infections to corneal perforation. Therefore, to counteract the aforementioned drawbacks, an ophthalmic solution for corneal greasing was developed, which simply consists of the combination of Riboflavin and methylcellulose, without the application of ultraviolet light, which I describe below.
- the present invention aims to provide an ophthalmic solution for thickening corneas, which comprises a combination of Riboflavin Sodium Phosphate; Powdered collagen and 5% methyl cellulose.
- the present invention also provides a method for preparing an ophthalmic solution for thickening corneas, which comprises a combination of Riboflavin Sodium Phosphate; Powdered collagen and 5% methyl cellulose
- the invention also provides the use of a combination of Riboflavin, Powdered Collagen and 5% Methyl Cellulose, to develop an ophthalmic solution, to thicken the corneas of a patient suffering from keratoconus, Post Lasik Ectasia, corneal ulcers or corneal thinning of any etiology.
- Figure 1 is a graph where the topography of a cornea of a patient suffering from keratoconus is illustrated.
- Figure 2 illustrates the topography of the cornea of Figure 1, but with 10 days of treatment with the ophthalmic solution of the present invention.
- Figure 3 illustrates the topography of the cornea shown in Figures 1 and
- Figure 4 shows the topography of a cornea with thinning caused by the application of laser beams to correct myopic astigmatism (Ectasia Post-Lasik).
- Figure 5 shows the cornea referenced in Figure 4 with 34 days of treatment with the ophthalmic solution of the present invention.
- Figure 6 the greasing of the cornea of Figures 4 and 5 is observed, with 4 months of treatment with the solution of this invention.
- Figure 7 illustrates the topography of a thinned cornea of a patient.
- Figure 8 illustrates the improvement of the cornea of Figure 7, with 35 days of application of the ophthalmic solution of the present invention.
- the present invention proposes an ophthalmic solution for thickening corneas, which is constituted of: Riboflavin phosphate Sodium; Powdered collagen; 5% methyl cellulose; Balanced saline solution; bidistilled water; And a conservative.
- One of the modalities of the ophthalmic solution of the present invention is that the ingredients that constitute it are in the following amounts: Riboflavin phosphate Sodium in 0.05%; 0.05% powdered collagen; 5% methylcellulose in 39.96%; The saline solution balanced by 19.98%; bi-distilled water by 29.97%; and the conservative at 9.99%.
- the amount of Riboflavin can be increased up to 0.1%, when the patient has severe keratoconus problems and the Saline Solution can vary from 9.99 to 19.98%.
- the stroma covers approximately 90% of the thickness of the cornea, hence it has a direct relationship with the origin of the keratoconus. Since the stroma of the cornea is mainly formed by collagen fibers, keratocytes and fundamental substance, we think of the direct and non-aggressive application of the nutrients generating these elements ophthalmic route. So that Riboflavin stimulates, through sunlight, the generation of new collagen fibers; The cellulose to nourish the Fundamental Substance and the hydrolyzed Collagen to nourish the stromal cell that is the keratocyte.
- the saline solution used in this formulation is the conventional ones, where its function is to irrigate the eye.
- the way to prepare the ophthalmic solution is the following: To prepare 10.01 mL of ophthalmic solution, we dilute 5 mg of collagen spray in 2 mL of the balanced saline solution and 2 mL of double-distilled water. Said dilution is made with the help of a thermo-agitator, for 15 min at 40 0 C, until homogenization of the mixture is achieved and allowed to cool from 20 to 22 0 C. On the other hand, we mix 5 mg of Riboflavin Sodium Phosphate, in 1 mL of double distilled water and 4 mL of 5% methylcellulose. The mixture was stirred at 9000 rpm for 20 min; then we filter in a conventional manner; and we stirred it again at 9000 rpm for 10 more minutes.
- the ophthalmic solution of the present invention actually greases the corneas that suffered from thinning caused by any factor.
- Example! Treatment of a patient with corneas suffering from keratoconus.
- a corneal topography was done with a device called ORSCAN to measure the thickness of its corneas (Figure 1), where it can be seen that the cornea had very thin areas, from 245 microns and 335 microns in the center of said cornea, this worn area is the one that has the red color in Figure 1. From that day, a drop was applied on the cornea, a drop every 4 h, of the ophthalmic solution to thicken corneas, of the present invention and after 10 days of continuous application, a second corneal topography was taken (Figure 2), where it was observed that the thin areas of the comet increased in thickness to 373 and 494, respectively.
- Example 2 Treatment of a patient with corneas affected by Ectasia Post-Lasik.
- Example 3 Treatment of a patient with thinning of corneas, of any etiology.
- Figure 7 shows a topography of a cornea that suffers a thinning of any etiology, where the center has a thickness of 498 microns, starting the treatment already described, for 35 days, when a second corneal topography was made ( Figure 8) , where it is appreciated that the central area of said cornea increased its thickness to 564 microns.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une solution ophtalmique permettant d'épaissir les cornées, laquelle est constituée d'une combinaison de Riboflavine, de Colagène, de méthyle-cellulose, d'une solution saline équilibrée, d'eau bi-distillée et d'un conservateur. Cette solution ophtalmique est conçue pour une application topique directement dans l'oeil d'un patient présentant des problèmes de keratoconus, des patients souffrant d'Ectasie Post Lasik, d'ulcères cornéens, d'amincissement de la cornée d'origines diverses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2008/000095 WO2010011119A1 (fr) | 2008-07-22 | 2008-07-22 | Solution ophtalmique pour épaissir les cornées |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2008/000095 WO2010011119A1 (fr) | 2008-07-22 | 2008-07-22 | Solution ophtalmique pour épaissir les cornées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010011119A1 true WO2010011119A1 (fr) | 2010-01-28 |
Family
ID=41570466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/MX2008/000095 WO2010011119A1 (fr) | 2008-07-22 | 2008-07-22 | Solution ophtalmique pour épaissir les cornées |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010011119A1 (fr) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8366689B2 (en) | 2008-09-30 | 2013-02-05 | Avedro, Inc. | Method for making structural changes in corneal fibrils |
| US8545487B2 (en) | 2007-12-05 | 2013-10-01 | Avedro Inc. | Eye therapy system |
| US8870934B2 (en) | 2009-10-21 | 2014-10-28 | Avedro, Inc. | Eye therapy system |
| US9020580B2 (en) | 2011-06-02 | 2015-04-28 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| US9044308B2 (en) | 2011-05-24 | 2015-06-02 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
| US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9707126B2 (en) | 2009-10-21 | 2017-07-18 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
| RU2633083C1 (ru) * | 2016-07-27 | 2017-10-11 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Средство офтальмологическое для диагностики травм и заболеваний роговой оболочки глаза |
| US10028657B2 (en) | 2015-05-22 | 2018-07-24 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
| US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
| US10258809B2 (en) | 2015-04-24 | 2019-04-16 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| US10350111B2 (en) | 2014-10-27 | 2019-07-16 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| US10729716B2 (en) | 2012-03-29 | 2020-08-04 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US11033429B2 (en) | 2010-09-30 | 2021-06-15 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US11179576B2 (en) | 2010-03-19 | 2021-11-23 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
| US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
| US11642244B2 (en) | 2019-08-06 | 2023-05-09 | Avedro, Inc. | Photoactivation systems and methods for corneal cross-linking treatments |
| US11766356B2 (en) | 2018-03-08 | 2023-09-26 | Avedro, Inc. | Micro-devices for treatment of an eye |
| US11931291B2 (en) | 2012-03-29 | 2024-03-19 | Epion Therapeutics, Inc. | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
| US12016794B2 (en) | 2018-10-09 | 2024-06-25 | Avedro, Inc. | Photoactivation systems and methods for corneal cross-linking treatments |
| US12042433B2 (en) | 2018-03-05 | 2024-07-23 | Avedro, Inc. | Systems and methods for eye tracking during eye treatment |
| US12144546B2 (en) | 2018-09-19 | 2024-11-19 | Avedro, Inc. | Systems and methods for eye tracking during eye treatment |
| US12171691B2 (en) | 2019-02-26 | 2024-12-24 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| US12293513B2 (en) | 2021-03-08 | 2025-05-06 | Avedro, Inc. | Systems and methods for generating patient-specific corneal cross-linking treatment patterns |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070087962A1 (en) * | 2005-10-17 | 2007-04-19 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
| US20070292496A1 (en) * | 2006-04-28 | 2007-12-20 | Universidad Complutense De Madrid | Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics |
| WO2008070848A2 (fr) * | 2006-12-07 | 2008-06-12 | Priavision, Inc. | Procédé et matériau d'augmentation de la structure cornéenne in situ |
-
2008
- 2008-07-22 WO PCT/MX2008/000095 patent/WO2010011119A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070087962A1 (en) * | 2005-10-17 | 2007-04-19 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
| US20070292496A1 (en) * | 2006-04-28 | 2007-12-20 | Universidad Complutense De Madrid | Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics |
| WO2008070848A2 (fr) * | 2006-12-07 | 2008-06-12 | Priavision, Inc. | Procédé et matériau d'augmentation de la structure cornéenne in situ |
Non-Patent Citations (1)
| Title |
|---|
| RAISKUP-WOLF, F. ET AL.: "Collagen crosslinking with riboflavin and ultraviolet- A light in keratoconus: Long-term results", J. CATARACT. REFRACT. SURG., vol. 34, May 2008 (2008-05-01), pages 796 - 801 * |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8545487B2 (en) | 2007-12-05 | 2013-10-01 | Avedro Inc. | Eye therapy system |
| US8366689B2 (en) | 2008-09-30 | 2013-02-05 | Avedro, Inc. | Method for making structural changes in corneal fibrils |
| US9498642B2 (en) | 2009-10-21 | 2016-11-22 | Avedro, Inc. | Eye therapy system |
| US8870934B2 (en) | 2009-10-21 | 2014-10-28 | Avedro, Inc. | Eye therapy system |
| US9707126B2 (en) | 2009-10-21 | 2017-07-18 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
| US11179576B2 (en) | 2010-03-19 | 2021-11-23 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
| US11033429B2 (en) | 2010-09-30 | 2021-06-15 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US12156834B2 (en) | 2010-09-30 | 2024-12-03 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US11135090B2 (en) | 2010-09-30 | 2021-10-05 | Cxl Ophthalmics, Llc | Ophthalmic treatment device, system, and method of use |
| US9044308B2 (en) | 2011-05-24 | 2015-06-02 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
| US10137239B2 (en) | 2011-06-02 | 2018-11-27 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| US9020580B2 (en) | 2011-06-02 | 2015-04-28 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| US11931291B2 (en) | 2012-03-29 | 2024-03-19 | Epion Therapeutics, Inc. | Ophthalmic treatment solution delivery devices and delivery augmentation methods |
| US10729716B2 (en) | 2012-03-29 | 2020-08-04 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US11497766B2 (en) | 2012-03-29 | 2022-11-15 | Cxl Ophthalmics, Llc | Compositions and methods for treating or preventing diseases associated with oxidative stress |
| US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US11219553B2 (en) | 2014-10-27 | 2022-01-11 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| US10350111B2 (en) | 2014-10-27 | 2019-07-16 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
| US12070618B2 (en) | 2015-04-24 | 2024-08-27 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| US11167149B2 (en) | 2015-04-24 | 2021-11-09 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| US10258809B2 (en) | 2015-04-24 | 2019-04-16 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| US10028657B2 (en) | 2015-05-22 | 2018-07-24 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
| US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
| US12214039B2 (en) | 2015-07-21 | 2025-02-04 | Advero, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
| RU2633083C1 (ru) * | 2016-07-27 | 2017-10-11 | Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" | Средство офтальмологическое для диагностики травм и заболеваний роговой оболочки глаза |
| US12042433B2 (en) | 2018-03-05 | 2024-07-23 | Avedro, Inc. | Systems and methods for eye tracking during eye treatment |
| US11766356B2 (en) | 2018-03-08 | 2023-09-26 | Avedro, Inc. | Micro-devices for treatment of an eye |
| US12144546B2 (en) | 2018-09-19 | 2024-11-19 | Avedro, Inc. | Systems and methods for eye tracking during eye treatment |
| US12016794B2 (en) | 2018-10-09 | 2024-06-25 | Avedro, Inc. | Photoactivation systems and methods for corneal cross-linking treatments |
| US12171691B2 (en) | 2019-02-26 | 2024-12-24 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
| US11642244B2 (en) | 2019-08-06 | 2023-05-09 | Avedro, Inc. | Photoactivation systems and methods for corneal cross-linking treatments |
| US12293513B2 (en) | 2021-03-08 | 2025-05-06 | Avedro, Inc. | Systems and methods for generating patient-specific corneal cross-linking treatment patterns |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010011119A1 (fr) | Solution ophtalmique pour épaissir les cornées | |
| O’Brart | Corneal collagen cross-linking: a review | |
| Elwan | Comparison between sutureless and glue free versus sutured limbal conjunctival autograft in primary pterygium surgery | |
| US9925201B2 (en) | Compositions and treatment for eye diseases and disorders | |
| EP2323642B1 (fr) | Utilisation de EDTA+tromethamine ou de photoactivateurs, associés à la riboflavine, pour la réticulation cornéenne dans le traitement du kératocône ou d'autres maladies ectasiques de la cornée | |
| ES2441227T3 (es) | Disolución oftálmica para la protección de las estructuras internas del globo ocular frente a los rayos UV-A o para el tratamiento del queratocono con una técnica de entrecruzamiento transepitelial | |
| JP2006514696A (ja) | 眼球の症状の予防及び治療のための眼科用製剤 | |
| US11110116B2 (en) | Hyperosmolar composition of hyaluronic acid | |
| US10973758B2 (en) | Methods of eye treatment using therapeutic compositions containing dipyridamole | |
| EP1187611B1 (fr) | Compositions ophtalmiques a base d'histamine et leurs utilisations | |
| Lane et al. | Prophylactic use of mitomycin-C in the management of a buttonholed LASIK flap | |
| CN105188702B (zh) | 使用双嘧达莫的用于治疗眼睛疾病的组合物 | |
| Williams | One-year results of laser vision correction for low to moderate hyperopia | |
| RU2672564C2 (ru) | Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина | |
| Amoils | Photorefractive keratectomy using a scanning-slit laser, rotary epithelial brush, and chilled balanced salt solution | |
| Wong et al. | Managing a child with an external ocular disease | |
| Patel et al. | Efficacy of limbal conjunctival autograft surgery with stem cells in primary and recurrent pterygium | |
| Hashemian et al. | The effect of topical diclofenac sodium 0.1% on the corneal epithelial healing after photorefractive keratectomy | |
| CA2731871C (fr) | Utilisation d'amplificateurs, possiblement associes a la riboflavine, et de compositions ophtalmiques correspondantes pour le traitement du keratocone ou d'autres maladies ectasiques de la cornee par reticulation corneenne | |
| Van Zyl et al. | Carbon dioxide laser keratectomy as a treatment option for equine corneal stromal abscessation: a comparison to lamellar keratectomy and penetrating keratoplasty | |
| Arab | Is Suturless and GluelessLimbal Conjunctival Autograft for Primary Pterygium Surgery Efficient and Safe | |
| Shaher et al. | Comparison of clinical results between flap-on and flap-off techniques of epithelial-laser in situ keratomileusis in correction of low to moderate myopia in eyes with thin corneas | |
| Patil et al. | A Study of limbal conjunctival autograft transplantation in primary pterygium | |
| Wickens | Dry eye treatments round-up | |
| TWI632913B (zh) | 用於眼部疾病或異常之組合物及其治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08793778 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/001742 Country of ref document: MX |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08793778 Country of ref document: EP Kind code of ref document: A1 |